Proposes Adding Carboetomidate, Methoxycarbonyl-Carboetomidate, and Allyl Etomidate as Second-Class Controlled Drugs
Summary
The Ministry of Health and Welfare of Taiwan published Notice No. 衛授食字第1151800123號 on April 27, 2026, proposing to add three etomidate analogues—Carboetomidate (碳依托咪酯), Methoxycarbonyl-Carboetomidate (甲氧羰基碳依托咪酯), and Allyl Etomidate (烯丙基依托咪酯)—as second-class controlled drugs under the Controlled Drugs Classification and Items list. The amendment is依据 the Controlled Drugs Management Act Article 3(2). Public comments are open for 14 days from gazette publication, with submissions to PengYH@fda.gov.tw or by mail to TFDA's Nangang, Taipei address.
About this source
GovPing monitors TFDA Taiwan News for new consumer protection regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 5 changes logged to date.
What changed
The proposal adds three specific etomidate analogue substances—Carboetomidate, Methoxycarbonyl-Carboetomidate, and Allyl Etomidate—to the second-class category of Taiwan's controlled drugs schedule. The amendment is issued under the authority of the Controlled Drugs Management Act and will subject these substances to the procurement, storage, reporting, and dispensing controls applicable to second-class controlled drugs. Parties manufacturing, distributing, prescribing, or dispensing these substances will face heightened compliance obligations once the amendment is finalized and takes effect. Comments are accepted for 14 days from gazette publication.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
公告資訊
- 本署公告
- 本署新聞
- 維護公告
- 活動訊息
- 預告法規沿革區
- 食藥膨風廣告專區
- 食藥闢謠專區
- 國內衛生局新聞
- 國外消費紅綠燈
- 本署徵才
- 重大政策
- 科技計畫
- 招標資訊
- 新聞API服務
- 國際與兩岸會議及研討會 目前位置： 首頁 > 公告資訊 > 本署公告 ### 預告修正「管制藥品分級及品項」(增列Carboetomidate等3項管制藥品) | 發布日期：2026-04-27 | 維護日期：2026-04-27 發布單位：管制藥品組
衛生福利部 公告 發文日期 ：中華民國115年4月27日 發文字號：衛授食字第1151800123號 附件： 主旨 ：預告修正 「管制藥品分級及品項」草案 依據：行政程序法第一百五十一條第二項準用第一百五十四條第一項。 公告事項： 一、修正機關：衛生福利部。 二、修正依據：管制藥品管理條例第三條第二項。 三、「管制藥品分級及品項」修正草案如下：
(一)增列 碳依托咪酯（ Carboetomidate ）為第二級管制藥品 。 (二)增列 甲氧羰基碳依托咪酯 （Methoxycarbonyl-Carboetomidate）為第二級管制藥品。 (三)增列 烯丙基依托咪酯（ Allyl Etomidate ）為第二級管制藥品 。 四、本案另載於本部網站「衛生福利法規檢索系統」網站(https://mohwlaw.mohw.gov.tw/)下「法規草案」網頁、本部食品藥物管理署網站「公告資訊」下「本署公告」網頁及國家發展委員會「公共政策網路參與平臺─眾開講」網頁(https://join.gov.tw/policies/)。
五、上述修正品項，為配合政府政策，避免管制空窗期影響科學上之需用，本公告周知期間為14日。對於本公告內容有任何意見或修正建議者，請於本公告刊登公報之次日起14日內陳述意見或洽詢：
(一)承辦單位：衛生福利部食品藥物管理署 (二)地址：臺北市南港區研究院路一段130巷109號 (三)聯絡人：彭技正 (四)電話：（02）27877611 (五)傳真：（02）26531180 (六)電子信箱：PengYH@fda.gov.tw
檔案下載
- 預告修正「管制藥品分級及品項」(增列Carboetomidate等3項管制藥品)
資訊內容對您是否有幫助：
| 極其有幫助 | 非常有幫助 | 有一定幫助 | 有點幫助 | 沒有幫助 |
驗證碼： 回上一頁
Named provisions
Get daily alerts for TFDA Taiwan News
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from TFDA Taiwan.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when TFDA Taiwan News publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.